Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Pearson slumps as Goldman says it expects only slight growth acceleration in Q3

(Sharecast News) - Educational publisher Pearson slumped on Wednesday as Goldman Sachs said in a results preview that it expects only slight growth acceleration in the third quarter, with a focus on the fourth quartrer to deliver full-year guidance.

The bank updated its estimates for Pearson ahead of 9M25 results in late October. It forecasts 3.5% growth in third-quarter group organic revenue, below Visible Alpha consensus data at +4.6% and implying 2.2% growth in nine-month group organic revenue.

"In particular, we are below Q3 consensus on ELL, A&Q and Virtual Learning," said Goldman.

The bank continued: "We expect the market will focus on: (i) the visibility on the organic revenue growth acceleration into Q4 and any potential update to the FY25 organic growth/adj. operating profit company guidance, (ii) an update on volumes from the new Pearson VUE customer wins (Salesforce, ServiceNow, and the Association of Social Work Boards), (iii) commentary around Fall 2025 US & International college enrolment trends, particularly in the backdrop of broadly more restrictive student migration policies, (iv) an update on the challenging end market trends across the high stakes English testing market and outlook into 2026."

For FY25, GS forecasts group organic growth of 3.7%, down from 3.8% previously. This is slightly below Visible Alpha consensus data at 3.9% growth and company guidance of 4.4% growth.

"Our FY25 adjusted operating profit forecast of £614mn (unchanged) at USD/GBP of 1.32 is broadly in line with current company guidance of £611mn and Visible Alpha consensus at £612mn," Goldman said.

At 1510 BST, the shares were down 3.6% at 1,046.73p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.